⚠ Evidence note: Human outcome data on longevity interventions is limited; most claims rest on surrogate markers or animal models. Nothing here is medical advice.
Mitochondria-Targeted Muscle Therapeutics
Current understanding
To be populated as evidence accumulates.
Evidence log
- 2026-09-22 — Asb2-KIF11 Axis Protects Against Heart Failure by Restoring Lysosomal Distribution and Mitochondrial Homeostasis.: cross-connection with kif11-inhibitors-cardiac: Positions KIF11 inhibition as an upstream lever for mitochondrial quality control via restored mitophagy, distinct from direct mitochondrial antioxidants. (novelty: 3)
- 2026-05-15 — Jintiange ameliorates age-related sarcopenia by inhibiting the cGAS-STING signaling pathway via maintaining mitochondrial homeostasis.: cross-connection with jintiange: Jintiange’s anti-sarcopenia effect is attributed to restored mitochondrial homeostasis, placing it alongside dedicated mitochondria-targeted muscle therapeutics. (novelty: 3)
Open questions
Related
Contributing findings
Targeting skeletal muscle wasting: Emerging therapeutics and translational challenges.
10-sep-2026
novelty 2
per-area 2
strengthens